Edition:
India

AmerisourceBergen Corp (ABC.N)

ABC.N on New York Stock Exchange

95.86USD
9:49pm IST
Change (% chg)

$1.27 (+1.34%)
Prev Close
$94.59
Open
$94.08
Day's High
$95.86
Day's Low
$94.04
Volume
54,262
Avg. Vol
290,146
52-wk High
$106.33
52-wk Low
$72.20

Latest Key Developments (Source: Significant Developments)

Amerisourcebergen Units Entered Amended & Restated Receivables Sale Agreement
Tuesday, 20 Oct 2020 

Oct 19 (Reuters) - Amerisourcebergen Corp ::AMERISOURCEBERGEN - ON OCT 16 UNITS ENTERED AMENDED & RESTATED RECEIVABLES SALE AGREEMENT, AMONG AMERISOURCEBERGEN DRUG CORPORATION & ASD SPECIALTY.AMERISOURCEBERGEN - AMENDMENTS ADDED ASD AS A NEW ORIGINATOR UNDER SECURITIZATION FACILITY.AMERISOURCEBERGEN CORP - SECURITIZATION FACILITY HAS A BASE LIMIT OF US$1,450 MILLION.AMERISOURCEBERGEN - SECURITIZATION FACILITY HAS OPTION TO INCREASE COMMITMENTS OF PARTICIPATING BANKS, BY ADDITIONAL US$250 MILLION.  Full Article

HHS Says Gilead Anticipates Producing Sufficient Quantities Of Veklury To Meet Current Needs
Thursday, 1 Oct 2020 

Oct 1 (Reuters) - HHS::HHS SAYS GILEAD ANTICIPATES PRODUCING SUFFICIENT QUANTITIES OF VEKLURY TO MEET CURRENT NEEDS, FUTURE DEMANDS FROM ANY WAVES OF SARS-COV-2 INFECTIONS.HHS SAYS COST OF VEKLURY WILL NOT CHANGE IN TRANSITION FROM U.S. GOVERNMENT OVERSIGHT OF ALLOCATION TO DIRECT COMMERCIAL SALES.HHS SAYS HOSPITALS WILL CONTINUE TO PAY NO MORE THAN GILEAD’S WHOLESALE ACQUISITION PRICE OF VEKLURY, ABOUT $3,200 PER TREATMENT COURSE.HHS SAYS AMERISOURCEBERGEN WILL REMAIN SOLE DISTRIBUTOR OF VEKLURY THROUGH END OF YEAR TO ENSURE CONSISTENCY & CONTINUITY OF DISTRIBUTION PROCESS.HHS SAYS FEDERAL GOVERNMENT OVERSIGHT OF THE ALLOCATION OF VEKLURY IS NOT REQUIRED BECAUSE THE DRUG IS NO LONGER A SCARCE RESOURCE.HHS SAYS BEGINNING OCT 1, 2020, AMERICAN HOSPITALS CAN PURCHASE VEKLURY (REMDESIVIR) DIRECTLY FROM DRUG’S DISTRIBUTOR.HHS SAYS CURRENT SUPPLY OF VEKLURY EXCEEDS MARKET DEMAND AS EVIDENCED BY RECENT ALLOCATION NUMBERS FROM HHS’ OFFICE OF THE ASPR.  Full Article

Emmaus Life Sciences Announces Addition Of Oncology Supply As Distributor Of Endari
Wednesday, 28 Aug 2019 

Aug 28 (Reuters) - Emmaus Life Sciences::EMMAUS LIFE SCIENCES - ANNOUNCED ADDITION OF ONCOLOGY SUPPLY, A PART OF AMERISOURCE BERGEN, AS A DISTRIBUTOR OF ENDARI (L-GLUTAMINE ORAL POWDER).  Full Article

McKesson, Cardinal, Amerisourcebergen Propose Paying $10 Bln To Settle Claims They Helped Fuel Opioid Epidemic - Bloomberg
Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - :DRUG DISTRIBUTORS MCKESSON, CARDINAL, AMERISOURCEBERGEN PROPOSE PAYING $10 BILLION TO SETTLE CLAIMS THEY HELPED FUEL OPIOID EPIDEMIC - BLOOMBERG REPORTER TWEET.  Full Article

PharMEDium Services Issues Voluntary Nationwide Recall
Wednesday, 3 Jul 2019 

July 2 (Reuters) - AmerisourceBergen Corp ::PHARMEDIUM SERVICES, LLC ISSUES VOLUNTARY NATIONWIDE RECALL OF 0.5 MG/ML HYDROMORPHONE HCL IN 0.9% SODIUM CHLORIDE 1 ML IN 3 ML BD SYRINGE DUE TO PRESENCE OF SULFITE.PHARMEDIUM SERVICES - VOLUNTARILY RECALLING 45 LOTS OF 0.5 MG/ML HYDROMORPHONE HCL IN 0.9% SODIUM CHLORIDE 1 ML IN 3 ML BD SYRINGE TO THE USER LEVEL.  Full Article

Federal Judge Enters Consent Decree Against Compounder Pharmedium Services For Violations At Multiple Facilities
Thursday, 23 May 2019 

May 22 (Reuters) - U.S. Food and Drug Administration::FEDERAL JUDGE ENTERS CONSENT DECREE AGAINST COMPOUNDER PHARMEDIUM SERVICES FOR VIOLATIONS AT MULTIPLE FACILITIES.FDA - CONSENT DECREE PROHIBITS PHARMEDIUM FROM MANUFACTURING DRUGS AT TENNESSEE FACILITY UNTIL IT COMPLETES CORRECTIVE ACTIONS, RECEIVES FDA AUTHORIZATION.  Full Article

AmerisourceBergen Q1 Adjusted Earnings Per Share $1.60
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - AmerisourceBergen Corp ::AMERISOURCEBERGEN REPORTS FISCAL 2019 FIRST QUARTER RESULTS.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $6.65 TO $6.85.Q1 ADJUSTED EARNINGS PER SHARE $1.60.Q1 GAAP EARNINGS PER SHARE $1.84.Q1 EARNINGS PER SHARE ESTIMATE $1.50 -- REFINITIV IBES DATA.ADJUSTED DILUTED EPS GUIDANCE NARROWED TO $6.65 TO $6.85 FOR FISCAL 2019.REVENUES OF $45.4 BILLION FOR Q1, A 12.2 PERCENT INCREASE YEAR-OVER-YEAR.Q1 REVENUE VIEW $43.84 BILLION -- REFINITIV IBES DATA.AMERISOURCEBERGEN -SEES FISCAL YEAR 2019 ADJUSTED OPERATING INCOME GROWTH IN LOW-SINGLE DIGIT PERCENT RANGE, DOWN FROM LOW- TO MID-SINGLE DIGIT PERCENT RANGE.AMERISOURCEBERGEN-UPDATED 2019 FINANCIAL GUIDANCE ON EVALUATION OF EXPECTATIONS AT PHARMEDIUM ON ASSUMPTION THAT MEMPHIS FACILITY TO NOT REOPEN THIS FISCAL YEAR.UPDATED FISCAL YEAR 2019 GUIDANCE INCORPORATES HIGHER THAN ANTICIPATED LEVEL OF SHARE REPURCHASES IN Q1 OF FISCAL YEAR.  Full Article

UPDATE 2-J&J to contribute up to $5 billion to potential U.S. opioid settlement

Oct 13 Johnson & Johnson said on Tuesday it will contribute up to $1 billion more to a potential settlement of lawsuits alleging it and other companies fueled the U.S. opioid epidemic, bringing its total payment to $5 billion.